Company intelligence / Profile preview
AnaptysBio, Inc.
- Ownership
- Public · ANAB
- Employees
- ~136
- Development stage
- Other
Overview
AnaptysBio is a clinical-stage biotechnology company specializing in immune cell-modulating antibodies for autoimmune and inflammatory diseases. Its pipeline includes multiple mid-stage assets such as Rosnilimab and ANB032 in Phase 2 trials, with Imsidolimab advancing into late-stage development for generalized pustular psoriasis. The company leverages its proprietary SHM-XEL platform for rapid antibody discovery and optimization. It has established royalty revenue streams from partnered programs like Jemperli with GSK and continues to expand through strategic licensing agreements.[1][2][4][5]
- Therapeutic areas
- GastroenterologyImmunologyDermatology
- Modalities
- Monoclonal antibodies (mAbs)Immune cell modulatorsCytokine antagonists[2][4][5][6]
- Industry
- Biotech
Drug pipeline
9 assets8 more assets in the full pipeline.
Partnerships
Financials
- Market cap
- $1.4B
- Total revenue
- $234.6M
- Enterprise value
- $1.5B
Beyond the preview
Go deeper on AnaptysBio, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AnaptysBio, Inc..